Liver transplantation (LT) is the treatment of endstage chronic liver disease and severe acute liver failure. Significant progress has been made in recent decades, leading to improved survival. (1) In France, for the 1993-2014 period, the survival of LT patients was 84.7% at 1 year, 73.2% at 5 years, and 62.4% at 10 years. During this period, there was an improvement in initial postoperative survival after LT, but survival after the first year remained similar. (2) This can be explained by the occurrence of late complications such as recurrence of initial disease, mainly hepatitis C, de novo malignancies, sepsis, and cardiovascular diseases that are known to be the main causes of late mortality. (3) (4) (5) The excess risk of post-LT de novo malignancy occurrence is now well known; the estimated risk for de novo malignancy is 1.4-4.9 times greater in LT recipients compared with the general population. (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) This excess risk is particularly high for nonmelanoma skin cancers and lymphoproliferative disorders. (18) Risk factors for de novo malignancies include immunosuppression with impaired immunosurveillance but also a number of patient factors including age, sex, latent oncogenic viral infections, history of tobacco and alcohol use, and underlying liver disease. Finally, de novo malignancies are one of the leading causes of longterm mortality of LT recipients, accounting for approximately 20% of deaths. (19) Many studies have evaluated the incidence of de novo malignancies in LT patients, but they often had a limited duration of follow-up or used nonexhaustive cohorts (single center). Using extensive data from the national health authority responsible for transplantations in France (Agence de la Biomédicine) for the 1993-2012 period, the aim of the present study was to describe the excess risk of solid organ de novo malignancies after LT, in comparison to the general population of France.
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Patients and Methods
StUDY popUlation
Patients with a first LT between January 1993 and December 2012 were identified from the national database of the French Agence de la Biomédecine, whose main purpose is the allocation of grafts, identification of biological and clinical information about transplantation, and follow-up of patients transplanted in France. Patients with a history of nonhepatic cancer before LT, patients for whom the indication for transplantation was hepatic cancer, patients who died within 30 days (because these deaths are mainly postoperative complications), as well as those who had a diagnosis of cancer within 30 days after LT (because these cancers were thought to be unrelated to transplantation) were excluded. Because available data do not differentiate lymphomas, myelomas, or other hematological disease, hematological malignancies were not investigated. In addition, we did not investigate nonmelanoma skin cancers because available estimations of cancer incidences in the general population in France do not include nonmelanoma skin cancers. Therefore, the present study was focused on solid organ de novo malignancies (excluding nonmelanoma skin cancers). The study end date was December 31, 2012 .
The data on post-LT malignancies were extracted from the Cristal database, which is completed once a year for each patient from the clinical charts of each transplant center. The presence of cancer is clearly identified, together with the date of diagnosis, and is coded using a thesaurus, with the possibility to add free text. The thesaurus used was mapped to the International Classification of Diseases, 10th Revision (ICD-10). The vital status is specified in the Cristal register. The study protocol was approved by the Comité Médical et Scientifique of the Agence de la Biomédecine.
analYSiS
Comparison between LT patients and the general population of France was performed using standardized incidence ratios (SIRs), defined as the ratio of the observed and expected number of malignancies standardized by age in 5-year increments, sex, and calendar year. The expected number of incident cancers was calculated by applying the cancer incidence rate in the French population for the same strata in person-years. National incidence rates were determined from the French Network of Cancer Registries, (20) standardized incidence rates estimated by year, cancer location, and stratified by 5-year age bracket.
The impact of initial liver disease leading to LT on the incidence of solid organ de novo malignancies was investigated by separating the initial diseases into 2 categories: alcoholic liver disease (ALD) versus others. In addition, a stratified analysis in function of the year of cancer occurrence, sex, and age group was conducted.
The χ 2 test was used to compare distributions, and the Student t test compared means. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC), and specifically, SIRs were calculated using a program adapted from Marchand. (21) 
Results
StUDY popUlation
In France, 15,977 patients underwent a LT from 1993 to 2012; 3264 patients were excluded because they underwent transplantation for hepatocellular carcinoma (HCC) or bile duct carcinoma or had a history of malignancy before LT, and 174 were excluded because this was the second (or more) transplantation (ie, retransplantation). In addition, 917 patients who died within 30 days or had a diagnosis of cancer within 30 days after LT were also excluded, as were 396 patients who had hematological malignancy (Fig. 1) . Therefore, the study population consisted of 11,226 LT patients from 24 centers in France, with 75,708 person-years of follow-up.
The sex ratio was approximately 2:1 (7325 men); the median age at time of LT was 48.6 years for women and 50.7 years for men (Table 1) . Patients were predominantly transplanted because of complications of cirrhosis, and especially ALD that affected 941 women (24.1%) and 3119 men (42.6%). At the end of the study period, 3025 (26.9%) had died, and 685 (6.1%) were lost to follow-up. Among the cohort of 11,226 patients, 1200 (10.7%) had a de novo solid organ malignancy after a mean 6.1 ± 4.3 years following LT (follow-up started 30 days postoperatively). The risk of de novo solid organ malignancy was significantly higher in men and in patients transplanted for ALD. The death rate was approximately 2 times higher in patients with de novo solid organ malignancy (48.8% versus 24.3%).
Sir oF SoliD orGan De novo MaliGnanCieS
Comparison to the General population overall
In comparison to the general population, the observed number of malignancies was significantly greater than expected ( Table 2 ). The locations of cancer for which the incidence was significantly increased were the larynx, esophagus, lung, lip-mouth-pharynx, kidney, and colon-rectum. Conversely, a significant decrease of incidence of liver cancers was observed compared with the general population. The calculation of the SIR by year of cancer occurrence found a significantly greater excess risk from 1998 that was relatively stable in subsequent years (Table 3) . 
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impact of Sex
When compared with the general population, the excess risk of laryngeal, esophageal, and lip-mouth-pharynx cancers was higher among women than among men ( Table 4 ). The incidence of colorectal cancer was significantly increased only among men, and the incidence of pancreatic cancer was significantly increased only among women. The incidence of lung cancer was significantly increased among men and women.
impact of initial liver Disease
Among the patients who underwent transplantation because of ALD (36.2%; n = 4060), the excess risk of malignancies overall (any type, among both sexes) was significantly greater than among those transplanted for an initial disease other than ALD (Table 5) . Patients transplanted for ALD had a significant excess risk for cancers of the larynx, esophagus, lip-mouth-pharynx, and lung. Because sex and initial liver disease had a strong impact on the risk of de novo solid organ malignancy, these 2 factors were analyzed together. Women transplanted for ALD had a significant excess risk for all malignancies compared with women transplanted for non-ALD, especially for the larynx, esophagus, lip-mouth-pharynx, and lung (Table 6 ). Men transplanted for ALD had a significant global excess risk for malignancies, especially for the larynx, esophagus, lung, and lip-mouth-pharynx cancers. The excess risk of malignancies was significantly lower for men transplanted for non-ALD (versus ALD), who had an excess risk only for kidney and lung cancers, in comparison to the general population. Women transplanted for non-ALD had a significant global excess risk for malignancies, without excess risk for any specific type, but a significantly reduced risk for breast cancer in comparison to the general population.
impact of age
The analysis by 5-year age groups found that the excess of cancer incidence in relation to the general population was more marked among the youngest; the highest SIR was for 25-to 29-year-olds and decreased with age (Table 7) . Men were impacted younger than women: The first significant SIR among men was for 25-to 29-year-olds whereas the first significant SIR occured first in women for 35-to 39-year-olds. There was no significant excess risk after 65 years in women and 75 years in men. From all pediatric LT recipients, only 3 presented a de novo malignancy, and only 1 before 20 years old. Table 8 reports the types of solid organ cancers according to a given age population. The excess risk of malignancies in the 20-to <40-year-old age group was significantly greater in comparison to the 40-to <60-year-old group and the ≥40-year-old group for larynx, kidney, and colorectal cancers.
Discussion
The present study, which is based on one of the largest reported populations of LT patients, found a significantly increased incidence of solid organ malignancies in these patients compared with the general population of France. In addition, we confirm the key role 
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of sex and initial liver disease in the development of de novo solid organ malignancies after LT. In addition, as expected, the risk of cancer increased with age, but the SIR decreased as the age advanced, illustrating that the risk of cancer in LT recipients is gradually approaching that of the general population with age. The present study did not include lymphoproliferative disorders, but it has been previously shown that there is an inverse SIR of solid organ cancers versus posttransplant lymphoproliferative disease based on age. (3) Other studies have previously evaluated the risk of de novo malignancies in LT recipients. These include single-center or registry-based studies, and almost all of them were retrospective. Variability in de novo malignancy incidence rates, or excess risks, reflects differences in the characteristics of the cohorts studied but also differences related to study design. For instance, among the patient characteristics, the factors impacting the types of cancers and incidence reported include age, sex, racial and geographical characteristics, and initial liver disease. These are also affected by methodological aspects, including the definition of de novo malignancy (for instance, we did not include nonmelanoma skin cancers and lymphoproliferative disorders), exclusion of cancers existing before LT (excluded herein, including cancers leading to transplantation, mainly HCC), duration of follow-up after LT and, in the case of SIR calculations, the control population used (we used the French general population as the control), and the method for identification of malignancies (we used data from the national registry of transplanted patients). We excluded in our study patients with a history of HCC in order to avoid the risk of bias regarding the occurrence of post-LT recurrence, which could have been misrecognized (in the database) and/or registered as de novo malignancy. It is of note that registry-based analyses yield higher SIR values, ranging from 2.2 to 4.9, (6) (7) (8) (9) (10) than other types of studies, which ranged from 1.4 to 3.7. (11) (12) (13) (14) (15) (16) (17) Herein, the overall SIR was close to the lower boundary of this range, which may be explained, at least in part, by the exclusion of lymphoproliferative disorders. In addition, differences may also be related to the characteristics of the study population; for instance, our French population included a large proportion of patients with ALD. However, it can be assumed that results from registry-based studies are the most relevant because of exhaustivity, and those based on national databases provide the largest populations, which avoid any center bias. In our study, the excess risk was stable More interesting is the analysis of the types of cancers that are significantly more frequently observed in LT patients, together with the factors influencing it. It must be pointed out that for 508 patients of our cohort, the type of cancer was not known or the type was known but the incidence in the general population was not available. This probably induced an underestimation in the calculation of SIR for some types of malignancies. Nevertheless, the findings of the present study are consistent with current data on post-LT cancers (18, 19, (23) (24) (25) because there was no significantly increased incidence in cancers of the pancreas, central nervous system, thyroid, ovary, breast, prostate, or testis as compared with the general population. We confirm here the dramatic increased risk of cancers related to alcohol and tobacco use (larynx, esophagus, lung, and lip-mouth-pharynx) (8, 22) in a cohort of patients where ALD was the most frequent indication for LT, even if the information of tobacco use was not available in the database, and this is a limitation of our study; indeed, patients transplanted for ALD are more likely to be smokers. (23) This increased risk has been previously demonstrated, not only when comparing LT recipients for ALD to the general population, but also to non-LT ALD patients with cirrhosis. (24) Interestingly, this excess risk appeared higher in women, and among women who underwent transplantation for a non-ALD indication, there was no increased risk for a particular type of cancer. This is highly relevant because ALD and nonalcoholic fatty liver disease will become the 2 main indications for LT worldwide very rapidly after the eradication of hepatitis C. (25) Nevertheless, the probable deleterious impact of tobacco in patients transplanted for non-ALD indications was also observed herein, with a significant excess risk of lung cancers in men. Because it has been reported that smoking withdrawal after LT may have a protective effect against the development of neoplasia, this could be highly recommended. (26) In our cohort, we also observed an excess risk of colorectal cancer. This has been previously reported in solid organ transplant recipients, (8) and this excess risk in LT recipients is clearly related to primary sclerosing cholangitis as the initial liver disease, with a SIR reaching 27.3 in highrisk patients with ulcerative colitis. (27) Nevertheless, Sint Nicolaas et al. reported that non-primary sclerosing cholangitis LT recipients have an increased risk compared with the general population. (28) Another point to note is that there was a reduced risk for liver cancers, but this was expected because patients transplanted for primary liver tumors were excluded and de novo liver carcinomas (especially HCC) are very rare after LT. (29) In LT recipients, de novo malignancies explain a large part of late mortality, (5, 19) which is suggested herein by the 2-fold higher rates of death. Transplant patients are more likely to be diagnosed at an advanced stage and to have therefore worse cancer-specific survival. (30) The reported site-specific 1-and 5-year 
ORIGINAL ARTICLE | 1435
survival rates for the most frequent solid organ cancers are 41%-43% and 16%, respectively, for lung cancers; 43%-78% and 56%, respectively, for oropharyngeal cancers; and 67%-80% and 52%, respectively, for gastrointestinal cancers. (5, 31) The present study adds to the literature on de novo malignancies after LT, but it should also be used to help transplant physicians improve management of LT patients. The increased risk and mortality associated with solid organ de novo malignancies underlines the need for both new immunosuppressive and surveillance strategies to reduce the risk and also detect tumors at earlier stages, leading to more effective treatments and better survival. Patients must be asked to maintain alcohol and tobacco abstinence of course, even if its beneficial effect may be delayed by more than a decade. (32) Large retrospective studies have suggested that immunosuppressive regimens based on mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus) could reduce the occurrence of de novo malignancies after kidney transplantation. (33, 34) Robust data in LT recipients are lacking, but some of the beneficial role of mTOR inhibitors has been suggested. (35, 36) Until now, there have been no standardized surveillance protocols for LT recipients. In addition, poor compliance to intense surveillance protocols could probably be a limitation. Nevertheless, some preliminary data are available and give a basis for further reflection. Finkenstedt et al. from Austria compared 2 surveillance protocols. The first was "intensified" and included an annual chest and abdominal computed tomography (CT) scan; urological, gynecological (pap smear and mammography), and dermatological examinations; and a colonoscopy every 5 years. The second was a "historical" protocol that included only an annual chest radiography and an abdominal ultrasonography. (12) Using intensified surveillance, fewer tumors were diagnosed at a late stage (46% versus 75%), and median survival following a diagnosis of nonskin cancer increased from 1.2 to 3.3 years. Similarly, Herrero et al. evaluated the impact of a multifaceted surveillance protocol (after 2006) including a urinalysis, a chest radiography, and an abdominal ultrasonography performed every 6 months for 1 year and annually thereafter; a mammography performed every 2 years; a colonoscopy every 7-10 years if no adenomas were detected; and, in patients with a smoking history, an annual otolaryngological evaluation and low-dose chest CT scan. (37) Patient survival was significantly increased in the case of cancer diagnosis through active surveillance when compared with patients diagnosed with symptomatic disease or incidentally. These are very promising results, yet we believe that surveillance protocols need to be personalized in order to be more efficient, but also less invasive, and therefore better accepted. For instance, Herrero et al. reported that the simple use of an annual lowdose chest CT scan in LT recipients with more than 10 pack-years of cumulative smoking history led to a diagnosis of early-stage lung cancer in 12% of patients. (38) On the other hand, our results suggest that women without a history of alcohol intoxication or smoking probably need no specific surveillance other than what is recommended outside transplantation (mammography, uterine cervical smears).
In conclusion, the present study, performed on a very large cohort with long follow-up, confirms that LT recipients have an excess risk of cancer compared with the general population, regardless of age, sex, and indication for transplantation, and this risk was greater among women. This underlines the need for primary prevention through modulation of immunosuppressive treatment but also personalized screening.
